[PDF] Top 20 Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives

... many years, cytokine-based therapies remained the standard approach for the manage- ment of mRCC, with only a small number of patients achieving a significant treatment response. However, since the early 2000s, a ... See full document

... rst-line treatment with the mTOR inhibitor temsirolimus was recom- mended, even though sunitinib, sorafenib, and pazopanib were frequently used ...rst-line treatment in patients with intermediate- and poor- ... See full document

... establish axitinib as a vital second line option in mRCC, with clinical activity superior to ...approved treatment for refractory mRCC – remains ...therapy, patient selection differed ... See full document

... the axitinib arm were hypertension (16% of patients), diarrhoea (11%), fatigue (11%), reduced appetite (5%), palmar-plantar erythrod- ysaesthesia (5%) and asthenia ...for axitinib dosing in this study built ... See full document

... with axitinib and ...between axitinib and sorafenib in post-sunitinib patients may have been extensively ...the axitinib group was significantly longer compared with the sorafenib ... See full document

... decreases axitinib exposure from 10% com- pared to overnight fasting, whereas high fat meal results in 19% higher exposure compared to an overnight ...fast. Axitinib absorption is pH dependent, with higher ... See full document

... Abstract: Renal cell carcinoma (RCC) is an aggressive malignancy compared to other urological malignancies and has been associated with poor responses to conventional cytotoxic chemo- ...TKI, ... See full document

... per patient treated with evero- limus to 84,136 GBP per patient treated with cabozantinib (Table ...case, treatment with cabozantinib resulted in most LYs and QALYs ...of axitinib and evero- ... See full document

... the cell lipid bilayer, leading to cell ...hepatocellular carcinoma (HCC) has been ...the treatment of HCC should still be viewed with ... See full document

... Single-agent axitinib is active and well tolerated as a second-line treatment for mRCC ...in treatment-naïve mRCC pa- tients who were treated with axitinib, when compared with those treated ... See full document

... ccRCC patient-derived xenograft were used to test these ...TKI, axitinib (36 mg/kg, two times per day); a c-Met inhibitor, crizotinib (25 mg/kg, one time per day); or ...expressing patient-derived ... See full document

... preferred treatment for pa- tients who have progressed on anti-VEGF TKI therapy, in the setting of a patient who had received sunitinib for one year, pazopanib for 8 months, and who remained with ECOG ... See full document

... RCC. Axitinib is the most recent drug to have received FDA approval and is indicated for the treatment of advanced RCC after failure of one prior systemic ...cytokine- treatment group when compared ... See full document

... Considering his age at onset and family history of skin disease and uterine myoma, and tumor histology, HLRCC was suspected, and thus he and his family underwent germline FH mutation testing, which demon- strated the ... See full document

... of axitinib was gradually reduced from 6 mg/day to 4 ...discontinued axitinib treat- ...of axitinib; however, CT findings in December 2017 revealed the size of metastases had increased again ...of ... See full document

... RCC. Axitinib is the most recent drug to have received FDA approval and is indicated for the treatment of advanced RCC after failure of one prior systemic ...cytokine- treatment group when compared ... See full document

... with axitinib and 4.7 months for those randomized to sorafenib. Axitinib conferred clinical benefit in terms of PFS to patients regardless of prior therapy such as sunitinib ...for axitinib and 9% ... See full document

... These data demonstrate that IL-17 inhibitors are ideal for psoriasis patients who require rapid clearance of their skin. Although a chronic disease, certain patients may benefit from more rapid response than others, such ... See full document

... the treatment of advanced RCC and other ...T cell activity in the tumor microenvironment, and inhibition of the PD-1/PD-L1 pathway can increase the anti-tumor immune response ...the treatment of ... See full document

... checkpoint treatment, namely, CTLA-4 and PD-1/PD-L1, probably caused by profound immunosuppression, which may be partly induced by myeloid-derived suppressor cells (MDSCs), a potential predictive marker for the ... See full document